Propella Therapeutics, Inc.
480 Hillsboro Street
1 article with Propella Therapeutics, Inc.
Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate CancerNext-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Propella Therapeutics, Inc. today announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.